



**World Health
Organization**

INN Working Document 07.213
Distr.: GENERAL
ENGLISH ONLY
19/06/2007

Addendum 1 to
***"The use of stems in the selection of International
Nonproprietary names (INN) for pharmaceutical
substances"*** WHO/PSM/QSM/2006.3

Programme on International Nonproprietary Names (INN)

***Quality Assurance and Safety: Medicines (QSM)
Medicines Policy and Standards (PSM)
World Health Organization, Geneva***

© World Health Organization 2007 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Addendum 1 to "The use of stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances" - WHO/PSM/QSM/2006.3

- 1/ *-cept*
- 2/ *-gliptin* (under *gli*)
- 3/ *-mapimod* (under *-imod*)
- 4/ *-rolimus* (under *-imus*)
- 5/ *-mulin*
- 6/ *pris*
- 7/ *-tril/-trilat*
- 8/ *-viroc* (under *vir*)

cept ***receptor molecules, native or modified (a preceding infix should designate the target)***

S.7.0.0

- ber-* VEGF receptors
aflibercept (96)
- co-* complement receptors
mirococept (91)
- far-* subgroup of interferon receptors
bifarcept (86)
- lefa-* lymphocyte function-associated antigen 3.receptors
alefacept (84)
- na-* interleukin-1 receptors
rilonacept (95)
- ta-* cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) receptors
abatacept (91), *belatacept* (93)(!)
- vir-* antiviral receptors
alvircept sudotox (69)

N.B.: *-nercept* stem already selected for Tumour Necrosis Factor antagonist (see p 113)

Under gli *antihyperglycaemics*
- gliptin **dipeptidyl aminopeptidase–IV inhibitors**

M.5.2.0

(a) *alogliptin (96), denagliptin (94), saxagliptin (92), sitagliptin (94),
vildagliptin (90)*

Under imod *immunomodulators, both stimulant/suppressive and stimulant*
-mapimod **mitogen-activated protein (MAP) kinase inhibitors**

S.7.0.0

(a) *balamapimod (96), pamapimod (96), doramapimod (88)(50), semapimod (89)*

Under imus *immunosuppressants (other than antineoplastics)*
-rolimus **immunosuppressants, rapamycin derivatives**

S.7.0.0

(a) *everolimus (82), pimecrolimus (81), sirolimus (69), tacrolimus (66)
temsirolimus (94), zotarolimus (94)*

-mulin **antibacterials, pleuromulin derivatives**

S.6.0.0

(a) *azamulin (54), pleuromulin (35), retapamulin (91), tiamulin (35),
valnemulin (74)(36)*

(b) *nonathymulin (56), thymostimulin (45)*

-pris- **steroidal compounds acting on progesterone receptors (excluding
-gest- compounds)**

Q.2.0.0

(a) *aglepristone (70), asoprisnil (88), asoprisnil ecamate (89), lonaprisan (97),
onapristone (58), toripristone (61), ulipristal (96)*

(c) *epristeride (69), saprisartan (72), and the stem -pristin selected for
antibacterials, pristinamycin derivatives*

Under vir *antivirals (undefined group)*
-viroc **CCR5 receptor antagonists**

S.5.3.0

(a) *ancriviroc (92), aplaviroc (94), maraviroc (94), vicriviroc (94)*

tril/trilat **endopeptidase inhibitors**

H.3.0.0

-dotril *candoxatril (62), candoxatrilat (62)
dexecadotril (73), ecadotril (68), fasidotril (74),
racecadotril (73)*
-lutril *daglutril (90)*
-patril/-patrilat *gemopatrilat (84), ilepatril (95), omapatrilat (78),
sapatrilat (74)*
